Travere Therapeutics

TVTX

Market cap $2.44B

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 6-9. In focal segmental glomerulosclerosis (FSGS), the Company will present: A late-breaking analysis from the DUPLEX Study demonstrating that patients treated with FILSPARI® (sparsentan) were more likely to reach proteinuria levels under 0.

Travere (TVTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 228,600 shares of its common stock to 43 new employees, consisting of inducement stock options to purchase an aggregate of 50,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 178,600 shares of its common stock. These induceme.

SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX #igan--CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidelines define diagnostic criteria, treatment goals and treatment approaches, aiming for progress f.

FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO , Sept.

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.

Initiating coverage on Travere Therapeutics with a "Buy: rating, citing strong growth potential for its kidney drug Filspari (sparsentan). Company's Filspari is FDA-approved for IgAN, with Q2 2025 U.S. net product revenues growing by 165% year-over-year to $71.9 million. A key catalyst is the January 13, 2026 PDUFA date for Filspari's sNDA in FSGS, potentially making it the first approved treatment for this rare kidney disorder.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 69,300 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted.

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.